Clinical Report: Tirzepatide's Impact on Pulmonary Embolism and DVT

Overview

This multicenter cohort study found that tirzepatide use is associated with a significantly lower risk of pulmonary embolism and deep vein thrombosis compared to lifestyle intervention alone in patients with type 2 diabetes and obesity.

Background

Venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT), is a significant cause of morbidity and mortality, particularly in patients with obesity and type 2 diabetes. These patients are at an increased risk due to factors such as endothelial dysfunction and chronic inflammation.

Data Highlights

Key Findings

• Tirzepatide was associated with a significantly lower 12-month risk of pulmonary embolism compared to lifestyle intervention alone (RR, 0.215).
• There was a similar reduction in the risk of deep vein thrombosis (RR, 0.303).
• No statistically significant difference was observed for superficial vein thrombosis.
• Findings for pulmonary embolism and deep vein thrombosis remained significant in a 90-day landmark analysis.
• In a comparator analysis with semaglutide, tirzepatide showed a significantly lower risk of deep vein thrombosis.

Clinical Implications

Clinicians should consider the findings when evaluating treatment options for patients with type 2 diabetes and obesity.

Conclusion

Tirzepatide use is associated with a lower risk of pulmonary embolism and deep vein thrombosis compared to lifestyle intervention alone.

Related Resources & Content

1. Frontiers | Tirzepatide and Reduced Risk of Pulmonary Embolism and Deep Vein Thrombosis: A Multicenter U.S. Cohort Study
2. Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on the risk of venous thromboembolism in patients with obesity: a real-world cohort study
3. 2026 Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults - Professional Heart Daily | American Heart Association
4. conexiant — Tirzepatide Linked to Lower Cardiorenal Events
5. The New Gastroenterologist — Comparative Gastrointestinal Risk of GLP-1 Receptor Agonists and Tirzepatide
6. the new gastroenterologist — Tirzepatide outperforms semaglutide for weight loss
7. conexiant — Tirzepatide Linked to Greater QoL Gains vs Dulaglutide
8. Tirzepatide Linked to Lower Cardiorenal Events
9. Comparative Gastrointestinal Risk of GLP-1 Receptor Agonists and Tirzepatide
10. Tirzepatide outperforms semaglutide for weight loss
11. 2026 Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults - Professional Heart Daily | American Heart Association
12. Frontiers | Tirzepatide and Reduced Risk of Pulmonary Embolism and Deep Vein Thrombosis: A Multicenter U.S. Cohort Study
13. Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on the risk of venous thromboembolism in patients with obesity: a real-world cohort study
14. Glucagon-like peptide 1 receptor agonists and risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials - ScienceDirect